Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 4/1997

01-07-1997 | ORIGINAL ARTICLE

Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy

Authors: R. A. Beveridge, John A. Miller, Arthur N. Kales, Richard A. Binder, Nicholas J. Robert, Janet Heisrath-Evans, Kathy Koczyk-Scripka, Steven Pashko, Michael J. Norgard, Harry M. Barnes, William R. Taylor, Keith A. Thompson, L. F. Smith, Winston M. Ueno, Robert F. Dobrzynski, Robert D. Warren, Daniel Katcher, Patrick J. Byrne, David M. Dunning, Stanley H. Winokur, Julian L. Lockey, Richard J. Cambareri, Thomas P. Butler, Robert J. Meister, John M. Fiegert

Published in: Supportive Care in Cancer | Issue 4/1997

Login to get access
Metadata
Title
Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy
Authors
R. A. Beveridge
John A. Miller
Arthur N. Kales
Richard A. Binder
Nicholas J. Robert
Janet Heisrath-Evans
Kathy Koczyk-Scripka
Steven Pashko
Michael J. Norgard
Harry M. Barnes
William R. Taylor
Keith A. Thompson
L. F. Smith
Winston M. Ueno
Robert F. Dobrzynski
Robert D. Warren
Daniel Katcher
Patrick J. Byrne
David M. Dunning
Stanley H. Winokur
Julian L. Lockey
Richard J. Cambareri
Thomas P. Butler
Robert J. Meister
John M. Fiegert
Publication date
01-07-1997
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 4/1997
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/PL00009894

Other articles of this Issue 4/1997

Supportive Care in Cancer 4/1997 Go to the issue

LETTER TO THE EDITOR

Postoperative bacteremia in cancer patients with solid tumors undergoing surgery: risk factors, etiology and outcome in 276 patients

MEETING HIGHLIGHTS

Psycho-Oncology at Wall Street: Third World Congress of Psycho-Oncology, New York, 4–6 October 1996

ORIGINAL ARTICLE

Effect of postchemotherapy nausea and vomiting on health-related quality of life

FORTHCOMING MEETINGS

Forthcoming meetings

REVIEW ARTICLE

Medical futility and appropriate medical care in patients whose death is thought to be imminent

EDITORIAL

Orphan topics in supportive care: how about xerostomia?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits